Qurient Co., Ltd.

Lead Discovery Center Gmbh

Institut Pasteur Korea

Qli5 Therapeutics Ag

Yeejin Jeon

Jaeseung Kim

Kiyean Nam

Dongsik Park

Mooyoung Seo

Gunther Zischinsky

Jan Eickhoff

SaeYeon Lee

Jeongjun Kim

Donghoon Yu

Young-In Yang

Seohyun Ahn

Doohyung Lee

Jiye Ahn

Hana Kim

Uwe Koch

Jung Yoon Kim

Sangchul Lee

Peter Nussbaumer

Carsten Schultz-Fademrecht

Sunhee Kang

Bert Klebl

Axel Choidas

Hwan Kyu Kang

Gahee Choi

Anke Unger

Sung-Jun Han

Minjung Seo

Jeongjea Seo

Yunmi Lee

Chun-won Jung

Yeong-in Yang

Robert Huber

Jung Hwan Kim

Chun-Won Jung

Yeong-In Yang

Wongyun Ahn

Seung-Joo Lee

Julian Engel

Carsten Degenhart

The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.

Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase

The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; Xand Xare independently, at each occurrence, CRor N; Y is C-Calkylene, wherein alkylene is optionally substituted with one to two C-Calkyl groups; Ris selected from the group consisting of hydrogen, halogen, C-Calkoxy, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R, n being 0 or 1; Ris selected from the group consisting of hydrogen, halogen, C-Calkyl, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R; Ris selected from the group consisting of hydrogen, hydroxyl, OR, &#x2014;NRR, C-Calkoxy, C-Calkyl, C-Ccycloalkyl, C-Chaloalkyl, &#x2014;C(O)NHR, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Rgroups; and Ris selected from the group consisting of &#x2014;NH, &#x2014;N(R)(V)R, &#x2014;NH(V)&#x2014;OR, &#x2014;NHC(O)R, and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease. 

2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors

The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

Quinoline derivatives as TAM RTK inhibitors

Growing community of inventors

Gyeonggi-do, South Korea

Yeejin Jeon